Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Deferred Taxes (2017 - 2023)

Lineage Cell Therapeutics' Deferred Taxes history spans 8 years, with the latest figure at $3000.0 for Q4 2023.

  • For Q4 2023, Deferred Taxes changed N/A year-over-year to $3000.0; the TTM value through Sep 2024 reached $3000.0, up 100.11%, while the annual FY2025 figure was -$5.3 million, N/A changed from the prior year.
  • Deferred Taxes reached $3000.0 in Q4 2023 per LCTX's latest filing, up from -$1.8 million in the prior quarter.
  • In the past five years, Deferred Taxes ranged from a high of $3000.0 in Q4 2023 to a low of -$4.4 million in Q1 2019.
  • Average Deferred Taxes over 4 years is -$1.2 million, with a median of -$1.0 million recorded in 2021.
  • Peak YoY movement for Deferred Taxes: surged 79.82% in 2020, then crashed 400.0% in 2021.
  • A 4-year view of Deferred Taxes shows it stood at -$991000.0 in 2019, then decreased by 4.84% to -$1.0 million in 2020, then increased by 3.75% to -$1.0 million in 2021, then skyrocketed by 100.3% to $3000.0 in 2023.
  • Per Business Quant, the three most recent readings for LCTX's Deferred Taxes are $3000.0 (Q4 2023), -$1.8 million (Q1 2023), and -$1.0 million (Q3 2021).